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Purpose: Our objectives are to assess (1) the acceptability and feasibility of dietary interventions for
patients undergoing radiation therapy (RT), and (2) the impact of dietary interventions on patient
reported outcomes, toxicities, and survival.
Methods: A PICOS/PRISMA/MOOSE selection protocol was used to include articles that evaluate adding
dietary interventions to patients receiving RT. Acceptability was defined as (# accepting/# approached);
feasibility was (# completing/# approached). Patient-reported outcomes were reported based on ques-
tionnaires used in each study and survival was measured from the date of diagnosis until death in each
study. Level of evidence was assessed with Center for Evidence-Based Medicine (CEBM) criteria.
Results: Sixteen articles were included; among these, 2027 patients were approached regarding the inter-
vention, and 1661 accepted (81.9%); of these, 1543 (92.9%) completed the prescribed diet + RT course. The
most common cancers included were gynecological, head and neck, and gastrointestinal. For patients
with pelvic cancers, a high fiber diet may improve diarrhea (CEBM level 1b). Enteral nutrition formula,
including formulas with proteins such as L-arginine, lipids such as eicosapentaenoic acids, glucids, and
ribonucleotides, may help prevent of malnutrition in head and neck cancer patients undergoing RT (level
2b). Vitamin C and b-carotene may reduce of xerostomia in head and neck cancer patients; however, the
studies evaluating these vitamins included vitamin E; which increases all-cause mortality (level 2b). No
dietary intervention for cancer patients receiving RT has been shown to improve survival.
Conclusion: There are limited data to support safe and efficacious use of dietary interventions during RT.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Introduction
In 2019, an estimated 1,762,450 new cases of cancer will be
diagnosed in the United States [1]. Radiation therapy (RT) is used
in 60% of cancer patients, and is associated with acutely pro-
inflammatory toxicities known to negatively impact patient
quality of life (QOL), including dermatitis, esophagitis, gastritis,
diarrhea, and cystitis. Increased fatigue and poor QOL are surro-
gates of survival [2,3]; further, RT may increase fatigue and worsen
QOL. For patients receiving RT, if QOL can be improved, then over-
all survival may increase as well.
Since the early 2000s, there has been an increased focus on the
use of dietary interventions to decrease toxicities and improve
outcomes of cancer patients [4]. For patients receiving RT, certain
dietary interventions are hypothesized to minimize toxicity, while
increasing cancer cell death, thereby widening the therapeutic
window, potentially improving survival [5,6]. As of 2019, there
are no recommendations from the National Comprehensive Cancer
Network (NCCN), the American Society for Radiation Oncology
(ASTRO), or the European Society for Radiation Oncology (ESTRO)
regarding the integration of dietary changes in the treatment reg-
imen for cancer patients undergoing RT [7]. There are, however,
recommendations for clinical practice made by the Academy of
Nutrition and Dietetics.
The purpose of this paper is to synthesize the evidence regard-
ing dietary interventions for cancer patients receiving RT. Specifi-
cally, we focus on interventions on the level of macromolecules
(i.e. changes in dietary fat/carbohydrate/protein/fiber levels) and
micromolecules, such as vitamins. Our objectives are to assess
(1) the acceptability, feasibility, and safety of dietary interventions
for patients undergoing RT, and (2) the impact of dietary interven-
tions on patient reported outcomes and toxicities related to RT. We
provide summary recommendations of all dietary interventions.
The results of this work may be used to supplement the guidelines
of the NCCN, ASTRO, ESTRO, and the Academy of Nutrition and
Dietetics [8].
Methods
Literature selection
The Population, Intervention, Control, Outcome, Study (PICOS)
design approach was used to define the inclusion criteria (Supple-
mentary Table 1). Additionally, a systematic search using the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) literature selection process was conducted (Supplemen-
tary Fig. 1).
We searched for full-text medical literature (excluding
abstracts) with human subjects from 1960 to 2018 in PubMed
for the terms [(‘‘cancer” and (‘‘radiation therapy” or ‘‘radiother-
apy”) and (‘‘diet” or ‘‘nutrition” or ‘‘food” or ‘‘supplement” or ‘‘vita-
min”)]. The terms were in titles or in MeSH headings. After
identifying 389 articles initially, three authors (TA, MC, KM)
screened each study and excluded any with the following features:
(1) full manuscripts that could not be obtained or were not avail-
able online, (2) duplicate or updated studies (in which case the
most recent version was used), (3) not written in English, (4) lack-
ing patient reported outcomes, (5) systematic reviews and meta-
analyses (though these were searched to find eligible articles),
(6) abstract alone, (7) non-randomized studies, and (8) no use of
RT. Additionally, some relevant articles were included from the ref-
erence lists of selected PubMed papers. The studies were then
reviewed by a senior author (NZ) and discussed among the group.
Of the 389 articles, 373 studies were not eligible, resulting in 16
total studies that met the inclusion criteria [9–24].
Data abstraction and analysis
From the 16 studies, characteristics of patients (e.g. age, gen-
der), cancer (e.g. disease site, stage), treatment (e.g. RT doses,
chemotherapy), dietary intervention (e.g. vitamins, supplements),
patient-reported outcomes (PROs), toxicity, and other outcomes
were coded. Dietary interventions in a clinical setting sit within a
comprehensive, individualized nutritional consultation which
encompasses nutritional screening, anthropometry and review of
the clinical picture and medical history. The key dietary interven-
tions used are: dietary counselling (diet modification/fortification
techniques/eating strategies), oral nutritional supplementation,
and reactive nutritional support in the form of nasoenteric feeding,
gastrostomy or jejunostomy tube feeding or total parenteral nutri-
tion for cases where oral intake is not possible. Dietary interven-
tions that involved a single supplement, such as amino acids or
antioxidants, were coded as ‘‘micronutrient” interventions, while
interventions changing the content of an entire meal, such as low
fiber or fat, were coded as ‘‘macronutrient” interventions.
For objective 1, acceptability was defined as: (the number of
patients agreeing to perform the dietary intervention + RT)/(the
number of eligible participants). Feasibility was defined as: (num-
ber of patients who completed the dietary intervention + RT)/
(number agreeing to perform the dietary intervention + RT). There
were four papers that did not report adherence [9,10,21,24]. Four
papers reported a feasibility rate for those who completed the
study, with compliance ranging from 9% to 93% [12,18,20,22].
The remaining studies only included data for participants who
maintained a particular level of compliance, ranging from 33% to
100% [11,19,16,17]. For reference, all values are listed in Table 1.
For objective 2, we assessed patient reported outcomes, toxici-
ties, and survival per the primary endpoint listed in each study
(listed in Table 1). Toxicities were recorded using the Common Ter-
minology Criteria for Adverse Events (CTCAE) scale, attributable to
the addition of the dietary modification, per the assessment of the
authors of the primary study. QOL was most commonly measured
pre- and post-treatment by the European Organisation for
Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire- C30 (QLQ-C30) and QLQ-PR25. Adverse effects of
RT were reported with Radiation Therapy Oncology Group (RTOG)
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Table 1
Summary of studies evaluating RT +/ dietary interventions.
Author, Year Cancer Dietary Intervention
vs Control Group
Concurrent
Treatment (n)
Diet type
(-molecule)
n
control
n
diet
n
screened
n
accepted
(%)
n
completed
(%)
Primary endpoint(s) Results of intervention vs control
Rubio, 2013 [9] Breast Glutamine
supplementation vs
placebo
Tamoxifen (12)
and/or
chemotherapy
(6)
Micro- 8 9 20 17 (85) 17 (100) Skin radiation
injury
Unclear improvement in cosmesis,
patients receiving oral Gln scored an
average of 0.9 ± 0.2 vs 1.4 ± 0.2 in the
placebo group (P < .05).
Fuchs-Tarkovsky, 2013 [10] Cervical Antioxidants (b -
carotene, vitamin C/
E, selenium) vs
placebo
Cisplatin (103) Micro- 54 49 103 103
(100)
103 (100) Oxidative stress,
hematological
toxicity, and QOL
Antioxidants improve QOL, but not other
endpoints.
Ishikawa, 2016 Esophageal Amino acid-rich
elemental diet vs
oral rinse
Chemotherapy
(17) + RT (16)
Micro- 16 17 NR 36 (NR) 33 (92) Oral mucositis Amino acid-rich elemental diet does not
improve mucositis, sarcopenia.
Bairati, 2005 [12], 2006 [13]
Meyer, 2007 [14]
Head &
neck
Vitamin E (a -
tocopherol), b-
carotene vs placebo
Pre-RT surgery
(32)
Micro- 263 272 NR 540 (NR) 535 (99) Occurrence and
severity of acute
effects of radiation
therapy
a -tocopherol increases all-cause
mortality
b-carotene reduces mucositis and local
recurrence
Chung, 2016 [15] Head &
neck
Vitamin E (a -
tocopherol) + C vs
placebo
Chemotherapy
(30)
Micro- 20 25 76 52 (68) 45 (87) Xerostomia Vitamin C + E reduce xerostomia acutely
Imai, 2014 [16] Head &
neck
HMB/Arg/Gln vs
none
Cisplatin (34) Micro- 18 16 40 40 (100) 34 (85) Grade 3 dermatitis HMB/Arg/Gln did not prevent grade 3
dermatitis
Vasson, 2014 [17] Head &
neck,
esophagus
Arginine, omega-3
fatty acid,
nucleotides- vs
placebo
Surgery
(unknown)
Micro- 13 15 47 37 (79) 28 (76) Nutritional status,
and functional
capacity.
Arginine/omega-3/nucleotides improve
weight loss, but do not improve
mucositis, other outcomes.
Demers, 2013 [18] Mixed
pelvic
Bacterial probiotics
vs placebo
Surgery (81),
chemotherapy
(120)
Micro- 89 150 410 246 (60) 239 (97) Diarrhea Probiotics may reduce diarrhea.
Garcia-Peris, 2016 [19] Mixed
GYN
Fiber (prebiotic) vs
placebo
Surgery (38) Macro- 18 20 47 46 (98) 38 (83) Diarrhea/stool
consistency
Fiber improves stool consistency and
diarrhea.
McGough, 2008 [20] Mixed
pelvic
Amino acid-based
formula vs normal
diet
Chemotherapy
(18)
Micro- 25 25 77 50 (65) 50 (100) Acute GI toxicity Amino acid-based formula does not
improve GI toxicity.
Muecke, 2010 [21] Mixed
GYN
Selenium
supplementation vs
no supplementation
Surgery (81) Micro- 42 39 108 81 (75) 81 (100) Survival Selenium does not impact survival.
Wedlake, 2012 [22] Mixed
pelvic
Low fat diet vs
modified fat diet vs
normal fat diet
Chemotherapy
(59)
Macro- 25 50 374 117 (31) 75 (64) Acute GI toxicity
(IBDQ)
Low or modified fat diet does improve GI
toxicity
Wedlake, 2017 [23] Mixed
pelvic
High-fiber diet vs
habitual-fiber diet vs
low-fiber diet
Chemotherapy
(121)
Macro- 53 106 583 166 (28) 159 (96) Acute and chronic
GI toxicity (IBDQ)
High-fiber diet reduces acute* and
chronicy GI toxicity
Petterson, 2014 [24] Prostate Reduced insoluble
dietary fiber, lactose,
soluble fiber vs
normal diet
Pre-RT
endocrine
therapy (69)
Macro- 55 51 142 130 (92) 106 (86) GI toxicity
(diarrhea,
constipation,
bloating, blood in
stools), QOL
Dietary intervention does not change GI
toxicity or QOL.
* Baseline to 5–7 weeks.
y 1 year after completion of RT.
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Acute Radiation Morbidity Scale and CTCAE questionnaires. Gas-
trointestinal (GI) adverse events were reported most commonly
using the GI Side Effects Questionnaire [24], Inflammatory Bowel
Disease-Questionnaire (IBD-Q) [25], and Vaizey Incontinence
Questionnaire [26].
Assessment of the risk of bias
The risk of bias for each study included was assessed using the
Cochrane’s ‘‘Risk of Bias” Assessment Tool, which uses 6 domains
to rank bias as low, medium, or high risk. These domains include:
selection bias (i.e. use of randomization), performance bias (i.e.
blinding of participants and study personnel), detection bias (i.e.
blinding of outcome assessors), attrition bias (i.e. incomplete out-
come data collection), reporting bias (i.e. selective reporting of
some outcomes but not others, depending on the nature and direc-
tion of the results) and other additional sources of bias (i.e. dissim-
ilarities in groups at baseline).
All 16/16 studies avoided biasing the selection process by ran-
domizing the participants. 9/16 studies blinded participants, while
8/16 studies blinded the assessors. 15/16 studies avoided attrition
bias by obtaining outcomes from more than 85% of their partici-
pants. Finally, 15/16 studies reported on similarity between groups
at baseline. These findings are summarized in Table 2. A hetero-
geneity assessment was not performed because the measurement
of endpoints varied among the included studies.
Results
Studies and patients
The 16 studies included in the analysis were published from
2005 to 2017 across 10 countries, including USA [9], Sweden
[27], Canada [13,14], Korea [15], Japan [11,16], Mexico [10], Spain
[19], Germany [21], France [17], and the UK [20,22,23]. In total, the
16 studies included 1567 patients, with 857 in the intervention
groups and 710 in the control groups. The mean age of all partici-
pants was 61.7 years. Cancer types included were breast [9], pros-
tate [27], head/neck [12–17], gynecological [10,19,21], mixed
pelvic [18,20,22,23], and esophageal [11], with the largest percent-
age of papers focusing on head and neck cancers (6/16). Dietary
interventions were grouped into two categories, macronutrient
(4/16 studies) and micronutrient (12/16).
Objective 1: Acceptability and feasibility of dietary interventions for
patients receiving RT
All studies included the number of patients initially
approached, except for four [9,10,14,16]. Among those that
reported the number of patients approached, there were 2027
patients approached, of which 1661 accepted (81.9%); of these,
1543 (92.9%) completed the prescribed diet + RT course. From a
cancer perspective, the studies looking at head/neck and gyneco-
logical cancers had the highest acceptability (100%), while studies
examining prostate cancers had an acceptability of 91.5%. As a
function of both cancer type and intervention type, the overall fea-
sibility for all studies was >75%, with the exception of the 2012
study published by Wedlake et al., which reported an overall feasi-
bility rate of 64%. In this study, compliance was >75% for the low-
and moderate-fat intake group arms; however, the compliance for
the normal fat diet was 21% and 0% for women and men, respec-
tively. Participants in this group consumed less than the targeted
fat intake. These results may be due to underreporting of fat intake.
These results are summarized in Table 1.
Objective 2: Patient reported outcomes, toxicity, and survival of
patients receiving dietary interventions during RT
Outcomes of interest
The most commonly reported patient reported outcomes were
GI toxicity, diarrhea alone, and QOL. GI toxicity, as measured by
standardized questionnaires such as IBD-Q, IBDQ-B, and RTOG,
was improved in 1/4 studies [23], and unchanged in 3/4 studies
[20,22,27]. In a mixed pelvic cancer population, neither an
amino-acid supplementation nor a low-fat diet appeared to have
any effect on GI toxicity [20,22]; however a high fiber diet
appeared to improve GI toxicity in this population [23]. In the
2017 study published by Wedlake et al., the authors found that a
high-fiber diet, in comparison to a low-fiber or habitual fiber diet,
resulted in a significantly smaller change in IBDQ-B scores in
patients receiving pelvic RT from before to after RT completion,
indicating an improvement in GI toxicity scores. Diarrhea, as
Table 2
Assessment of risk of bias of included studies.
Selection bias
(randomization)
Performance bias
(blinding of subjects)
Detection bias
(blinding of assessors)
Attrition bias
(outcomes obtained)
Other biases
(similar at baseline)
Rubio [9] NR
Pettersson [24]
Pettersson [30]
Bairati [12]
Bairati [13]
Chung [15]
Imai [16]
Meyer [14]
Fuchs-Tarlovsky [10] NR
Garcia-Peris [31]
Garcia-Peris [19]
Muecke [21]
Demers [18]
Mcgough [20]
Vasson [17]
Wedlake [22]
Wedlake [23]
Ishikawa [11]
= Low risk of bias.
= High risk of bias.
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measured separately from other GI symptoms, was improved in
3/3 studies [18,19,21]. Muecke et al. found that supplementation
with selenium improved diarrhea severity as measured by the
NCI’s Common Toxicity Criteria, though this was not the primary
outcome of their study. Demer et al. and Garcia-Peres et al. found
that probiotic and prebiotic supplements improve stool consis-
tency as measured by the Bristol Stool Chart. QOL improved in
1/3 studies [10], and remained unchanged in 2/3 studies [17,27].
Fuchs-Tarlovsky et al. found that antioxidant supplementation
improved QOL as measured by the EORTC QLQ-C30 in women with
cervical cancer [10].
Outcomes as a function of dietary intervention type
The most common interventions were supplementation with
antioxidants (5/16) [10,12–15], amino acids [11,16,17,20] and fiber
[19,23,27]. Of the 5 studies that assessed antioxidant supplementa-
tion, only 2 found significant improvements in any outcomes
[10,15]. Fuchs-Tarlovsky et al. found that QOL in patients with cer-
vical cancer was significantly higher in the group receiving antiox-
idant supplementation compared to the control group, as
measured by the EORTC QLQ-C30. Chung et al. found that vitamin
C and E supplementation significantly reduced xerostomia in
patients with head and neck cancer 6 months post-radiation as
measured by a patient reported xerostomia questionnaire (mean
reduction in score of 2.7) and an observer-rated xerostomia score
(mean reduction in score of 1.3). Bairati et al. did not find any sig-
nificant improvements; however, they did find a significant
increase in all-cause mortality (HR = 1.38, 95% CI 1.03–1.85) in
patients with head and neck cancers who took a-tocopherol, a type
of vitamin E, with or without b-carotene supplements [13]. This
data suggests that a-tocopherol increases all-cause mortality; no
significant increase in mortality was seen, however, with the addi-
tion of b-carotene.
Of the 5 studies that used amino acid supplementation, 3 found
significant improvements in any outcome [9,16,17]. Imai et al.
found that amino acid supplementation significantly decreased
the severity of dermatitis as measured by the CTCAE-4, whereas
Vasson et al. found that amino acid supplementation significantly
improved weight-loss when combined with omega-3 fatty acids
[16,17]. Rubio et al. found that glutamine alone helped decrease
skin toxicity as measured by the Radiation Therapy Oncology
Group in patients with breast cancer [9]. Amino acid supplementa-
tion did not have any effect on mucositis, sarcopenia, or GI toxicity
across all studies [11,20].
Three studies evaluated fiber intake [19,23,27]. One study found
that reduced fiber intake combined with a reduced lactose intake
had no effect on GI toxicity as measured by the EORTC QLQ-30
and QLQ-PR25 at 12- or 24-months post radiation [27]. A second
study found that a high fiber diet significantly improves GI toxicity
as measured by the IBD-Q at the end of RT [22]. Taken together,
these two studies suggest that a diet high in fiber may help
decrease GI toxicity experienced by patients with mixed pelvic
cancers immediately after RT, whereas a low-fiber intake will have
no long-term impact on GI toxicity. The third study found that pre-
biotic supplementation resulted in decreased diarrhea as measured
by the EORTC QLQ-C30 in patients with mixed gynecological can-
cers [19].
Outcomes as a function of disease site
Of the 16 studies, the most common cancers studied were gyne-
cological [10,18–23], head and neck [12–17], GI [18,20,22–23], and
prostate [18,20,27]. Five of the papers included patients with
metastatic cancer [11,16,17]. Of the 7 studies looking at gynecolog-
ical cancer patients, improvements were seen in diarrhea (3/7), GI
toxicity (2/7) and QOL (1/7) [10,18,19,21–23]. Diarrhea and GI tox-
icity were improved by high-fiber diets, low-fat diets, probiotics,
and selenium supplementation; however, most of these studies
evaluated diarrhea as a secondary endpoint, and the strongest
prospective evidence currently only exists for fiber [19,21–23]. Of
the 5 studies looking at patients with head and neck cancer,
improvements were seen in xerostomia (1/5), dermatitis (1/5),
and weight-loss (1/5) [15–17]. Of the 4 studies looking at GI cancer
patients, improvements were seen in GI toxicity (2/4) and diarrhea
(1/4) through protective effects of dietary interventions [18,22,23].
GI toxicity was reduced in the population consuming high-fiber
and low-fat diets [22,23]. These studies suggest a protective effect
of high-fiber, low-fat diets and probiotics against GI toxicity and
diarrhea in patients receiving RT for a cancer diagnosis. Of the 3
studies analyzing the effects of diet + RT on participants with pros-
tate cancer, improvements were only seen in diarrhea (1/3) [18].
This was in patients taking probiotic supplements.
Survival
Adverse events due to dietary interventions were uncommon
among the studies included in this review. Of those included,
two studies assessed survival as an outcome. Bairati et al. reported
an overall 38% increase in all-cause mortality (HR 1.38, 95% CI
1.03–1.85) for individuals who consumed a-tocopherol or b-
carotene alone, or in conjunction with other supplements [13]. Par-
ticipants who reported use of a-tocopherol alone had the greatest
increase in overall all-cause mortality (HR = 1.43, 95% CI 0.98–
2.07). Second, Muecke et al. [21] found no difference in survival
with the addition of selenium for gynecological cancer patients
receiving RT.
Discussion
There are currently no guidelines recommending the integra-
tion of dietary modifications for patients receiving RT. This is the
first review that provides some consensus in support of dietary
modifications in reducing adverse toxicities experienced as a con-
sequence of RT. We found that patients receiving RT are accepting
of dietary interventions and that dietary studies have an accept-
ability rate of 82% and a high feasibility rate of 93%. However, there
are limited data showing that any of these interventions improve
toxicity. Further, no home-based dietary intervention improves
survival.
There is level 1b evidence (randomized controlled trial with
narrow confidence interval) that a high fiber diet improves RT-
related diarrhea. The amount of fiber considered a high fiber diet
(>18 g/day), however, is lower than the recommended 25–
30 g/day. The improvement in RT-related diarrhea is therefore
more likely due to the nonstarch polysaccharides rather than the
amount of fiber. There is level 2b evidence (individual cohort
study) that a solution of proteins, lipids, and sugars may improve
RT-related malnutrition and weight loss. This finding supports
the European Society for Clinical Nutrition and Metabolism
(ESPEN) guidelines on nutrition in cancer patients which recom-
mend a protein intake of 1.0–1.5 g/kg/day to maintain energy
and substrate requirements [28]. There is also level 2b evidence
that vitamin C and b-carotene may improve xerostomia, though
studies using these interventions combined the drugs with vitamin
E (tocopherol), which has been shown to increase the risk of cancer
development, cancer recurrence, and all-cause mortality [29]. This
suggests that vitamin E supplementation should be monitored in
individuals at risk for cancer and undergoing treatment for cancer.
Further testing should be done to determine the threshold above
which vitamin E consumption increases risk for recurrence. No
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dietary intervention for cancer patients receiving RT has been
shown to improve survival (Table 3).
Quality of life affects patient treatment compliance and comple-
tion. Only one study in our review found a statistically significant
increase in quality of life secondary to a dietary intervention.
Donovan et al. found that prostate cancer patients who received
RT initially had decreased quality of life measured by sexual func-
tion, bowel function, urinary voiding, and nocturia. Patients
reported, however, recovery in these symptoms after six months
of RT [30]. Similar improvements in quality of life after initial
decreases with RT are seen in head and neck and breast cancer
patients [31,32].
Weight loss in cancer patients is associated with an unfavorable
prognosis, increased toxicity of anti-cancer treatments resulting in
reductions or interruptions of scheduled treatment and reduced
quality of life (ESPEN). Ishikawa et al. found a decrease in body
mass index (BMI) and body fat mass (FM) after chemoradiation
treatment. Lean body mass (LBM), however, increased in patients
receiving Elental (amino-rich elemental diet) compared to patients
receiving azulene oral rinse for oral mucositis. For head and neck
cancer patients who received immunomodulating enteral nutrition
(IEN), Vasson et al. reported statistically significant increases in
weight, BMI, and LBM compared to patients receiving standard
enteral nutrition (SEN). For malnourished patients, increases in
weight, BMI, and LBM were seen with IEN and SEN. Wedlake
et al. did not find a statistically significant different in body weight
or BMI at baseline or at the end of RT for patients receiving low- or
habitual-fiber diets but the difference in the change in BMI
between groups was significant. We recommend future studies fol-
low the ESPEN guidelines in reporting weight status as a measured
outcome due to the effect on treatment prognosis.
While there is one published paper evaluating the nutritional
recommendations for adult patients undergoing cancer treatment
at NCCN-member institutions, no systematic review about dietary
intervention specifically during RT exists. Other studies in our sys-
tematic review only involved a single study population. Champ
et al. found that only four of 21 NCCN-member institutions pro-
vided nutritional guidelines - two recommended low-fat, high-
carbohydrate diets with 5:1 and 6:1 carbohydrate to fat ratios,
while the other two institutions recommended a 1:1 ratio of carbo-
hydrate to fat, focusing on weight maintenance during treatment.
Their findings are comparable to ours in that there is limited data
and consensus of dietary recommendations for patients undergo-
ing cancer treatment. Our work, however, expands to include
micronutrient and specific RT-site recommendations as well as
assesses the implementation potential of dietary interventions in
RT oncology departments by reporting on acceptability, feasibility,
and safety. In the ‘‘Clinical Guide to Oncology Nutrition,” a chapter
discusses the benefits of nutrition on radiation therapy and dis-
cusses the need for adequate caloric and protein intake, particu-
larly focusing on supplementing a patient’s specific deficiency to
ameliorate or prevent side effects. The authors recommend glu-
tamine and zinc sulfate supplementation, with evidence on mini-
mization or prevention or mouth sores and mucositis and to help
the return of taste, respectively, in head and neck cancer patients.
It also discusses amifostine clinical trials that show infusions
reduce the incidence of xerostomia and side effects in pelvic radi-
ation [33].
This study is not without limitations. One limitation of this sys-
tematic review is the dearth of available literature regarding nutri-
tional interventions for patients during RT. Only 19 papers
encompassing 16 studies were published that met the inclusionary
criteria for this systematic review. The included studies had small
sample sizes and were predominantly limited to gynecological,
head and neck, GI, and prostate cancer, with one study conducted
in a breast cancer population. Individual studies varied in regards
to: follow-up time, intervention type, cancer site and stage, patient
demographics, and outcome measures used (i.e., quality of life is
measured using different scales). Due to this heterogeneity, a
meta-analysis could not be conducted and definitive conclusions
cannot be drawn at this time. Further studies are needed to
further elucidate the effect of various nutritional interventions on
patient-reported and clinical outcomes in patients receiving
chemotherapy.
Conclusion
This systematic review is the first summary of dietary interven-
tions for cancer patients receiving RT. For patients with pelvic can-
cers, a high fiber diet may improve diarrhea [23].
Immunomodulating enteral nutrition formula, including proteins
such as L-arginine, lipids such as eicosapentaenoic acids, glucids,
and ribonucleotides may help prevent of malnutrition in head
and neck cancer patients undergoing RT [17]. Lastly, vitamin C
[15] and b-carotene [14] may reduce of xerostomia in head and
neck cancer patients; however, the studies evaluating these vita-
mins included vitamin E, which increases all-cause mortality
[12,13]. No dietary intervention for cancer patients receiving RT
has been shown to improve survival. Future research is warranted
to help establish evidence-based nutritional guidelines for oncolo-
gists and their patients with the goal of limiting RT toxicities.
Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.
Table 3
Recommendations regarding dietary intervention during RT.
Condition Associated
Cancer
Evidence-based strategies to reduce effects Patient
Sample
Size
Oxford Center of Evidence Based
Medicine (CEBM) level of evidence
Diarrhea Pelvic, GYN High fiber diet (18 g NSP*/d) [19,23] 197 1by
Malnutrition Head &
neck,
esophagus
Enteral nutrition formula, which includes proteins, (e.g. L-arginine), lipids (e.g.
eicosapentaenoic, docosahexaenoic acids), glucids (e.g. mono, disaccharides) and
ribonucleotides [17]
28 2b
Xerostomia Head & neck Possible improvement with Vitamin C (50 mg/d) [15] and b-carotene (6 mg/day)
[14] though the studies using them combined them with Vitamin E.
Notably, RT + vitamin E + b-carotene has been shown to increase all cause mortality
over RT alone [12,13]
580 2b
* Non-starch polysaccharide.
y Therapy/Prevention, Etiology/Harm: individual RCT (with narrow confidence interval).
 Therapy/Prevention, Etiology/Harm: individual cohort study (including low quality RCT; e.g., <80% follow-up).
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Appendix A. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.tipsro.2020.08.001.
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